Dimensional Fund Advisors LP Sells 45,236 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Dimensional Fund Advisors LP lowered its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 14.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 271,358 shares of the company’s stock after selling 45,236 shares during the quarter. Dimensional Fund Advisors LP owned about 0.88% of Medpace worth $111,784,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of MEDP. Signaturefd LLC raised its holdings in Medpace by 4.9% during the second quarter. Signaturefd LLC now owns 559 shares of the company’s stock valued at $230,000 after buying an additional 26 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in Medpace by 0.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock worth $1,787,000 after purchasing an additional 32 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in Medpace by 5.3% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 781 shares of the company’s stock worth $316,000 after purchasing an additional 39 shares during the last quarter. Journey Advisory Group LLC lifted its holdings in Medpace by 1.9% in the 2nd quarter. Journey Advisory Group LLC now owns 2,390 shares of the company’s stock worth $984,000 after purchasing an additional 44 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Medpace by 43.3% in the 1st quarter. GAMMA Investing LLC now owns 149 shares of the company’s stock worth $60,000 after purchasing an additional 45 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on MEDP shares. Guggenheim reduced their target price on Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a report on Wednesday, September 18th. Robert W. Baird reduced their target price on Medpace from $430.00 to $413.00 and set an “outperform” rating for the company in a report on Friday. Mizuho assumed coverage on Medpace in a report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 target price for the company. Finally, William Blair reiterated an “outperform” rating on shares of Medpace in a report on Wednesday, September 11th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $420.88.

Medpace Trading Down 1.0 %

MEDP opened at $361.95 on Tuesday. The stock has a market cap of $11.21 billion, a PE ratio of 36.90, a P/E/G ratio of 1.74 and a beta of 1.35. Medpace Holdings, Inc. has a 1 year low of $227.21 and a 1 year high of $459.77. The stock’s 50 day simple moving average is $376.50 and its 200-day simple moving average is $391.48.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.54 by $0.21. The business had revenue of $528.10 million for the quarter, compared to analysts’ expectations of $528.41 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. Medpace’s quarterly revenue was up 14.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.93 earnings per share. Equities analysts forecast that Medpace Holdings, Inc. will post 11.66 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.